AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18294230 — intervention group
Group type: COMPARATOR
Intervention: Sodium bicarbonate air-polishing (SBAP)
Number of subjects: 10
Study 18294230 — intervention group
Group type: COMPARATOR
Intervention: Hand-instrumentation
Number of subjects: 10
Study 18294230 — intervention group
Group type: COMPARATOR
Intervention: No treatment (negative control)
Number of subjects: 10
Study 16542188 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 227
Study 16542188 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 227
Study 16542188 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 227
Study 16542188 — intervention group
Group type: COMPARATOR
Intervention: Lamotrigine vs Placebo
Number of subjects: 227
Study 16542188 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine vs Lithium
Number of subjects: 227
Study 16542188 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine and Lithium
Number of subjects: 227
Study 12667663 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-beta 1a therapy
Number of subjects: 127
Study 10738212 — intervention group
Group type: EXPERIMENTAL
Intervention: HAI group (5‐fluorouracil (5‐FU) 500 mg/day for 4 days followed by a 3‐day rest, continued for 6 weeks)
Number of subjects: 19
Study 10738212 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 19
Study 10738212 — intervention group
Group type: EXPERIMENTAL
Intervention: HAI group
Number of subjects: 19
Study 10738212 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 19
Study 9433595 — intervention group
Group type: EXPERIMENTAL
Intervention: Sib-pair analysis
Number of subjects: 0
Study 9433595 — intervention group
Group type: EXPERIMENTAL
Intervention: Association studies
Number of subjects: 0
Study 8497668 — intervention group
Group type: COMPARATOR
Intervention: Procedural intervention
Number of subjects: 301
Study 8497668 — intervention group
Group type: COMPARATOR
Intervention: Procedural/Belief intervention
Number of subjects: 301
Study 8497668 — intervention group
Group type: EXPERIMENTAL
Intervention: Control group
Number of subjects: 301
Study 8497668 — intervention group
Group type: COMPARATOR
Intervention: Belief intervention
Number of subjects: 301
Study 3303926 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphotericin B plus flucytosine (0.3 mg/kg per day of amphotericin B and 150 mg/kg per day of flucytosine) for four weeks
Number of subjects: 194
Study 3303926 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphotericin B plus flucytosine (0.3 mg/kg per day of amphotericin B and 150 mg/kg per day of flucytosine) for six weeks
Number of subjects: 194
Study 3303926 — intervention group
Group type: EXPERIMENTAL
Intervention: Flucytosine toxicity
Number of subjects: 194
Study 3303926 — intervention group
Group type: EXPERIMENTAL
Intervention: Toxic reactions contributing to death
Number of subjects: 194
Study 3303926 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring recommendations
Number of subjects: 194
Study 3303926 — intervention group
Group type: EXPERIMENTAL
Intervention: Flucytosine initial dosing recommendations
Number of subjects: 194
Study 31050312 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily footbath with alkaline soap
Number of subjects: 97
Study 31050312 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily footbath with acidic soap
Number of subjects: 97
Study 31050312 — intervention group
Group type: COMPARATOR
Intervention: Simple bandage of gauze dressing
Number of subjects: 97
Study 28842722 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval walking training (IWT)
Number of subjects: 14
Study 28842722 — intervention group
Group type: COMPARATOR
Intervention: Continuous walking training (CWT)
Number of subjects: 14
Study 25112383 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical technique or mesh type for primary inguinal hernia repair (exact details not specified)
Number of subjects: 10810
Study 25112383 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-reported outcome measures (PROMs)
Number of subjects: 10810
Study 25112383 — intervention group
Group type: COMPARATOR
Intervention: Meta-analyses
Number of subjects: 10810
Study 21631599 — intervention group
Group type: EXPERIMENTAL
Intervention: Block-periodized multipurpose exercise program (EG, n=43)
Number of subjects: 85
Study 21631599 — intervention group
Group type: COMPARATOR
Intervention: Wellness-control program (CG, n=42)
Number of subjects: 85
Study 20659181 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphoric acid + opaque sealant (group I)
Number of subjects: 80
Study 20659181 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil S3 Bond + opaque sealant (group II)
Number of subjects: 80
Study 20659181 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphoric acid + clear sealant (group III)
Number of subjects: 80
Study 20659181 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil S3 Bond + clear sealant (group IV)
Number of subjects: 80
Study 19761688 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal femoral nail antirotation (PFNA)
Number of subjects: 121
Study 19761688 — intervention group
Group type: COMPARATOR
Intervention: Dynamic hip screw (DHS)
Number of subjects: 121
Study 17157802 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (80 mg zinc oxide, 2 mg cupric oxide)
Number of subjects: 0
Study 17157802 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 14962830 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid infusion
Number of subjects: 15
Study 12361201 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal 17beta-estradiol (100 microg)
Number of subjects: 24
Study 12361201 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 9825752 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 70
Study 9825752 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy
Number of subjects: 70
Study 8109546 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine
Number of subjects: 53
Study 8109546 — intervention group
Group type: COMPARATOR
Intervention: Control (no specific control mentioned)
Number of subjects: 53
Study 2572652 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyzine, 50 mg
Number of subjects: 12
Study 2572652 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine, 300 mg
Number of subjects: 12
Study 2572652 — intervention group
Group type: COMPARATOR
Intervention: Hydroxyzine plus ranitidine
Number of subjects: 12
Study 2572652 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 53172 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly dosed organo-heparinoid ointment and gel
Number of subjects: 513
Study 434431 — intervention group
Group type: EXPERIMENTAL
Intervention: R 33812 4 mg i.v. before anaesthesia
Number of subjects: 150
Study 434431 — intervention group
Group type: EXPERIMENTAL
Intervention: R 33812 8 mg i.v. before anaesthesia
Number of subjects: 150
Study 434431 — intervention group
Group type: EXPERIMENTAL
Intervention: R 33812 10 mg orally with premedication
Number of subjects: 150
Study 434431 — intervention group
Group type: COMPARATOR
Intervention: Diazepam 10 mg orally as premedication
Number of subjects: 150
Study 31253091 — intervention group
Group type: EXPERIMENTAL
Intervention: Galcanezumab 120 mg
Number of subjects: 1773
Study 31253091 — intervention group
Group type: EXPERIMENTAL
Intervention: Galcanezumab 240 mg
Number of subjects: 1773
Study 31253091 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1773
Study 28209505 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin (BTX) injection
Number of subjects: 50
Study 28209505 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatments plus gabapentin (group GPN)
Number of subjects: 50
Study 25596096 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic (Bifidobacterium lactis)
Number of subjects: 400
Study 25596096 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic (Bifidobacterium lactis plus inulin)
Number of subjects: 400
Study 25596096 — intervention group
Group type: EXPERIMENTAL
Intervention: Prebiotic (inulin)
Number of subjects: 400
Study 25596096 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 400
Study 25596096 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics, prebiotics, or synbiotic
Number of subjects: 400
Study 23798746 — intervention group
Group type: EXPERIMENTAL
Intervention: DOWN - 45 minutes of physical therapy + 30 minutes of treadmill with 5% descending slope
Number of subjects: 38
Study 23798746 — intervention group
Group type: COMPARATOR
Intervention: UP - 45 minutes of physical therapy + 30 minutes of treadmill with 5% ascending slope
Number of subjects: 38
Study 21840602 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluocinolone acetonide implant
Number of subjects: 255
Study 21840602 — intervention group
Group type: COMPARATOR
Intervention: Systemic corticosteroids plus immunosuppression
Number of subjects: 255
Study 19482895 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive group (n = 7)
Number of subjects: 16
Study 19482895 — intervention group
Group type: COMPARATOR
Intervention: Traditional group (n = 7)
Number of subjects: 16
Study 17503973 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided discontinuation strategy
Number of subjects: 131
Study 17503973 — intervention group
Group type: COMPARATOR
Intervention: Maintenance treatment
Number of subjects: 131
Study 15194574 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone 7 mg/day
Number of subjects: 167
Study 15194574 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 167
Study 12077577 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 (PGE(2)) applied intradermally (10(‐8)‐10(‐4) M)
Number of subjects: 16
Study 12077577 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 16
Study 9466515 — intervention group
Group type: EXPERIMENTAL
Intervention: Priming with recombinant vaccinia gp160LAI and boosting with recombinant gp120SF-2, gp120LAI, gp120MN, or gp160MN
Number of subjects: 56
Study 9466515 — intervention group
Group type: EXPERIMENTAL
Intervention: Boosting with gp120
Number of subjects: 56
Study 9466515 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination regimen with vac/env and gp120
Number of subjects: 56
Study 7621570 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocturnal infusion of octreotide (1-1.5 micrograms/kg body weight, subcutaneously)
Number of subjects: 9
Study 7621570 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocturnal infusion of octreotide
Number of subjects: 9
Study 2496951 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel (L‐NOG) 0.75 mg administered orally for 4 days during the periovulatory period (days 9, 11, 13, and 15)
Number of subjects: 72
Study 2496951 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel (L‐NOG) 0.75 mg administered orally for 4 days during the periovulatory period (days 11, 12, 16, and 19)
Number of subjects: 72
Study 2496951 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel (L‐NOG) 0.75 mg administered orally during the follicular or luteal phase
Number of subjects: 72
Study 2496951 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel (L‐NOG) 0.75 mg administered orally during the follicular phase
Number of subjects: 72
Study 2496951 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel (L‐NOG) administered during treatment
Number of subjects: 72
Study 1264926 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin B.P. 300 mg
Number of subjects: 17
Study 1264926 — intervention group
Group type: EXPERIMENTAL
Intervention: Claradin 150 mg
Number of subjects: 17
Study 1264926 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin B.P. 75 mg
Number of subjects: 17
Study 1264926 — intervention group
Group type: EXPERIMENTAL
Intervention: Aloxiprin 300 mg
Number of subjects: 17
Study 1264926 — intervention group
Group type: EXPERIMENTAL
Intervention: Claradin 50 mg daily for 12-15 days
Number of subjects: 17
Study 1264926 — intervention group
Group type: EXPERIMENTAL
Intervention: Claradin 25 mg daily
Number of subjects: 17
Study 1264926 — intervention group
Group type: EXPERIMENTAL
Intervention: All preparations
Number of subjects: 17
Study 1264926 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuation of treatment
Number of subjects: 17
Study 31902567 — intervention group
Group type: EXPERIMENTAL
Intervention: iTBS (intermittent theta burst stimulation) over the DLPFC for four weeks (20 daily sessions, 900 pulses per day)
Number of subjects: 126
Study 31902567 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation over the DLPFC
Number of subjects: 126
Study 30808379 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth intervention (initial SMS alert and reminders)
Number of subjects: 200
Study 30808379 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth intervention (follow-up email and SMS for non-adherents)
Number of subjects: 200
Study 28820793 — intervention group
Group type: EXPERIMENTAL
Intervention: Codeine (30 mg) plus acetaminophen (500 mg) orally 4 times per day for 4 days after PRK
Number of subjects: 80
Study 28820793 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 26253644 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-delivered acceptance and commitment therapy (iACT)
Number of subjects: 39
Study 26253644 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control (WLC)
Number of subjects: 39
Study 23652245 — intervention group
Group type: EXPERIMENTAL
Intervention: RA MU-Optimized plans
Number of subjects: 7
Study 23652245 — intervention group
Group type: COMPARATOR
Intervention: RA Clinical plans
Number of subjects: 7
Study 22115211 — intervention group
Group type: EXPERIMENTAL
Intervention: R2 sympathicotomy
Number of subjects: 121
Study 22115211 — intervention group
Group type: EXPERIMENTAL
Intervention: R3 sympathicotomy
Number of subjects: 121
Study 19278731 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (25 mg Zn/day)
Number of subjects: 60
Study 19278731 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine (approximately 140 mg/day) + Zinc supplementation
Number of subjects: 60
Study 19278731 — intervention group
Group type: COMPARATOR
Intervention: Imipramine (approximately 140 mg/day) + Placebo
Number of subjects: 60
Study 16374651 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal fixation
Number of subjects: 143
Study 16374651 — intervention group
Group type: COMPARATOR
Intervention: Total hip replacement (THR)
Number of subjects: 143
Study 15290454 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term low-dose daily 14-membered-ring macrolide therapy
Number of subjects: 90
Study 15290454 — intervention group
Group type: COMPARATOR
Intervention: Control group (no macrolide therapy)
Number of subjects: 90
Study 15290454 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemosensitivity testing on H. pylori strains
Number of subjects: 90
Study 12184425 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketac‐Endo (KE), without smear layer (smear ‐)
Number of subjects: 72
Study 12184425 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketac‐Endo (KE), with smear layer (smear +)
Number of subjects: 72
Study 12184425 — intervention group
Group type: EXPERIMENTAL
Intervention: AH 26, smear (‐)
Number of subjects: 72
Study 12184425 — intervention group
Group type: EXPERIMENTAL
Intervention: AH 26, smear (+)
Number of subjects: 72
Study 12184425 — intervention group
Group type: COMPARATOR
Intervention: nonprepared (negative control)
Number of subjects: 72
Study 12184425 — intervention group
Group type: COMPARATOR
Intervention: prepared but unfilled (positive control)
Number of subjects: 72
Study 9519356 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of LHRH agonist buserelin (nasal spray) and cyproterone acetate (Androcur), either continuously or for the first 2 weeks
Number of subjects: 0
Study 9519356 — intervention group
Group type: COMPARATOR
Intervention: Orchidectomy
Number of subjects: 0
Study 8128920 — intervention group
Group type: EXPERIMENTAL
Intervention: Lentinan (2 mg weekly for inpatients and 4 mg every other week for outpatients)
Number of subjects: 69
Study 8128920 — intervention group
Group type: COMPARATOR
Intervention: Control (no Lentinan)
Number of subjects: 69
Study 2475954 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lignocaine (5 mg/kg body-weight infused over 30 minutes)
Number of subjects: 10
Study 2475954 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline (same volume as lignocaine)
Number of subjects: 10
Study 1020050 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of adriamycin, vincristine and methotrexate (AVM)
Number of subjects: 24
Study 1020050 — intervention group
Group type: COMPARATOR
Intervention: Combination of vinblastine, bleomycin and mithramycin (VBM)
Number of subjects: 24
Study 1020050 — intervention group
Group type: EXPERIMENTAL
Intervention: AVM
Number of subjects: 24
Study 1020050 — intervention group
Group type: COMPARATOR
Intervention: VBM
Number of subjects: 24
Study 31628359 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual infusion (MI)
Number of subjects: 100
Study 31628359 — intervention group
Group type: COMPARATOR
Intervention: Pump infusion (PI)
Number of subjects: 100
Study 28640480 — intervention group
Group type: EXPERIMENTAL
Intervention: Involvement of ex-offender service user consultants in research
Number of subjects: 4
Study 28404199 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic ventral mesh rectopexy (n=38)
Number of subjects: 75
Study 28404199 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic posterior sutured rectopexy (n=37)
Number of subjects: 75
Study 24564746 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal positioning techniques
Number of subjects: 438
Study 24564746 — intervention group
Group type: COMPARATOR
Intervention: Usual care (expectant management)
Number of subjects: 438
Study 21673620 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical disc arthroplasty (BRYAN prosthesis)
Number of subjects: 120
Study 21673620 — intervention group
Group type: COMPARATOR
Intervention: ACDF
Number of subjects: 120
Study 19874444 — intervention group
Group type: EXPERIMENTAL
Intervention: Buffered esomeprazole (BE) 40 mg twice daily
Number of subjects: 10
Study 19874444 — intervention group
Group type: COMPARATOR
Intervention: Intravenous pantoprazole 40 mg bolus
Number of subjects: 10
Study 17551145 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin-based chemotherapy
Number of subjects: 2968
Study 17551145 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin-based chemotherapy
Number of subjects: 2968
Study 17551145 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin-based chemotherapy in patients with nonsquamous tumors
Number of subjects: 2968
Study 17551145 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin-based chemotherapy in patients treated with third-generation chemotherapy
Number of subjects: 2968
Study 16376772 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicuspid AS group
Number of subjects: 53
Study 16376772 — intervention group
Group type: COMPARATOR
Intervention: Tricuspid AS group
Number of subjects: 53
Study 12214931 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5% ethanolamine oleate
Number of subjects: 40
Study 12214931 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% ethanolamine oleate
Number of subjects: 40
Study 10088798 — intervention group
Group type: EXPERIMENTAL
Intervention: C-test (constant-load treadmill test, 3 km/hr; fixed grade of 12%)
Number of subjects: 50
Study 10088798 — intervention group
Group type: EXPERIMENTAL
Intervention: G-test (graded-exercise treadmill test, 3 km/hr; increase in grade of 3.5% every 3 minutes)
Number of subjects: 50
Study 7585843 — intervention group
Group type: EXPERIMENTAL
Intervention: augmented betamethasone dipropionate 0.05% lotion
Number of subjects: 197
Study 7585843 — intervention group
Group type: COMPARATOR
Intervention: clobetasol propionate 0.05% solution
Number of subjects: 197
Study 2209315 — intervention group
Group type: EXPERIMENTAL
Intervention: MaxEPA (10 g/day)
Number of subjects: 80
Study 2209315 — intervention group
Group type: COMPARATOR
Intervention: Olive oil (control)
Number of subjects: 80
Study 6996928 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone (10 mg tablets, 4 times daily)
Number of subjects: 98
Study 6996928 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone
Number of subjects: 98
Study 6996928 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study 31244434 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-ultraPEALut (1 mg/kg o.s.) administered 1h before LPS injection or 1h and 6h after LPS injection or 1h before LPS injection and 1h and 6h after LPS
Number of subjects: 0
Study 31244434 — intervention group
Group type: EXPERIMENTAL
Intervention: Glialia® (700 mg PEA + 70 mg luteolin)
Number of subjects: 0
Study 28728956 — intervention group
Group type: EXPERIMENTAL
Intervention: Ataluren (40 mg/kg per day, orally, three times daily)
Number of subjects: 230
Study 28728956 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matching placebo)
Number of subjects: 230
Study 28728956 — intervention group
Group type: EXPERIMENTAL
Intervention: Ataluren (40 mg/kg per day)
Number of subjects: 230
Study 26056125 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg pSDF-1
Number of subjects: 93
Study 26056125 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg pSDF-1
Number of subjects: 93
Study 26056125 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study 25230350 — intervention group
Group type: EXPERIMENTAL
Intervention: diclofenac (0.1%)
Number of subjects: 239
Study 25230350 — intervention group
Group type: EXPERIMENTAL
Intervention: pranoprofen (0.1%)
Number of subjects: 239
Study 25230350 — intervention group
Group type: COMPARATOR
Intervention: control, physiological normal saline solution
Number of subjects: 239
Study 25230350 — intervention group
Group type: EXPERIMENTAL
Intervention: diclofenac (0.1%) and epinephrine
Number of subjects: 239
Study 25230350 — intervention group
Group type: EXPERIMENTAL
Intervention: pranoprofen (0.1%) and epinephrine
Number of subjects: 239
Study 25230350 — intervention group
Group type: COMPARATOR
Intervention: control, physiological normal saline and epinephrine solutions
Number of subjects: 239
Study 22559159 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise therapy alone
Number of subjects: 0